The Drug Regulatory Authority of Pakistan (DRAP) has issued fresh safety alerts for three medicine and vaccine batches. Its latest notice, dated 2 November 2026, identifies Rhophylac 300 injection batch P100830101 as spurious. Earlier alerts flagged Influvac Tetra vaccine batch P13 and Vaxigrip Tetra vaccine batch Y4B34.
The warnings apply to the specific batches listed below. They do not mean that every pack sold under these brand names is counterfeit. Patients, pharmacists and healthcare facilities should check the batch number on the packaging before using or supplying an affected product.
DRAP’s latest fake medicine and vaccine alerts
| Product | Batch number | Alert date | What DRAP says |
|---|---|---|---|
| Rhophylac 300 injection | P100830101 | 2 November 2026 | The authorised company said this batch is not associated with it or its authorised distribution chain. |
| Influvac Tetra vaccine | P13 | 30 October 2026 | Verification with the authorised supplier found the batch to be spurious and outside the legitimate supply chain. |
| Vaxigrip Tetra vaccine | Y4B34 | 27 October 2026 | The company informed DRAP that this batch had never been imported or distributed in Pakistan. |
1. Rhophylac 300 injection — batch P100830101
In its 2 November alert, DRAP said the marketing authorisation holder, Hakimsons (Impex) (Pvt.) Ltd. of Karachi, informed the authority that batch P100830101 was not associated with its company and did not belong to its authorised product distribution. The pack purports to be manufactured by CSL Behring AG, Switzerland.
DRAP has classified the identified batch as spurious and directed its regulatory field force and provincial drug-control departments to conduct surveillance and remove the falsified product from the supply chain. The warning concerns batch P100830101, not every Rhophylac 300 pack.
2. Influvac Tetra vaccine — batch P13
DRAP’s 30 October alert concerns Influvac Tetra vaccine batch P13, which was purportedly manufactured by Abbott Biologicals B.V. in the Netherlands. The authority said verification with the authorised supplier confirmed that the batch was spurious and was not part of the legitimate supply chain. The alert also referred to the product being marketed and supplied through online channels.
Consumers should not use a pack bearing the identified batch number. Healthcare providers and pharmacies have been asked to remain alert to the product in their supply chains.
3. Vaxigrip Tetra vaccine — batch Y4B34
DRAP’s 27 October alert identifies Vaxigrip Tetra quadrivalent influenza vaccine batch Y4B34. Hoechst Pakistan Limited informed the regulator that the suspected batch had never been imported or distributed in Pakistan. The pack purports to be manufactured by Sanofi Winthrop Industrie, France.
Again, the alert is batch-specific. It should not be interpreted as a warning against every Vaxigrip Tetra pack or every influenza vaccine. Check the batch number and consult a licensed pharmacist or healthcare professional if there is any doubt.
What should consumers do if they have one of these batches?
- Check the exact batch number: Compare the number printed on the carton, label or pre-filled syringe packaging with the numbers in the table above.
- Do not use an identified batch: If your pack matches one of the listed batches, do not use it. Contact the prescribing doctor, pharmacist or healthcare provider for advice on a safe replacement.
- If it has already been used: Contact your healthcare provider promptly, particularly if the product was injected or administered as a vaccine. Report any suspected adverse event to the relevant health professional and regulator.
- Keep the packaging and receipt: Retain the product details and proof of purchase so the batch can be identified and reported accurately.
- Buy through licensed outlets: DRAP advises consumers to obtain therapeutic goods from licensed pharmacies and authorised retail outlets, and to seek professional advice if a product’s authenticity or condition is uncertain.
Do not stop a prescribed treatment or substitute another medicine on your own. If a pack matches a DRAP alert, avoid using that batch and contact the clinician responsible for the treatment so that the next step can be decided safely.
Will the new medicine barcode system help?
Pakistan’s pharmaceutical track-and-trace rollout requires applicable registered drug products manufactured locally or imported on or after 9 October 2026 to carry a 2D Data Matrix barcode and serial number. The code is intended to support identification and traceability through the supply chain.
DRAP has clarified that batches manufactured locally or imported before 9 October remain exempt from this particular barcode requirement and may continue to be imported, distributed and sold. Therefore, an older legitimate pack without the new code is not automatically counterfeit. Equally, a barcode should not replace checking an official safety alert or confirming a product with a licensed pharmacist. DRAP’s current compliance notice does not provide a consumer app name or public launch date, so avoid relying on unverified apps that claim to authenticate medicines.
Why checking batch numbers matters
A medicine’s brand name alone is not enough to establish that a particular pack is genuine. Batch identification helps patients and healthcare professionals distinguish a specific suspect lot from legitimate products with the same name. The safest response is to check the exact number, use licensed supply channels and seek professional advice whenever a product is named in a regulator’s alert.
Illustrative featured image: National Cancer Institute via Unsplash.
Official safety updates: DRAP’s official alerts and product-safety updates.